Factors Influencing Vaccine Hesitancy in China: A Qualitative Study

Overview

Journal Vaccines (Basel)

Date 2021 Nov 27

PMID 34835221

Citations 19

Authors

Jianli Wang

Qianqian Ji

Shuheng Dong

Shuangyu Zhao

Xinchen Li

Qiuqi Zhu

Sigui Long

Jingjing Zhang

Hui Jin

Affiliations

Soon will be listed here.

Abstract

Vaccine hesitancy has become a significant issue. We aimed to elucidate the factors influencing vaccine hesitation in Chinese residents and to analyze and recommend promotional strategies and measures. In total, 92 Chinese residents from 10 provinces were interviewed using semi-structured face-to-face interviews following a predetermined survey framework in this qualitative study. We found trust in vaccine safety, access to professional advice, and vaccine price and effectiveness to be the main factors influencing vaccine hesitation. Additionally, residents in areas with a higher per capita GDP tend to receive more social support, believe that vaccination is beneficial and can prevent diseases, pay more attention to whether the vaccine is safe and has undergone various clinical trials, and are more likely to seek advice from individuals with vaccination experience as opposed to their counterparts in areas with a lower per capita GDP. Notably, as per capita GDP rises, individuals become more concerned about the price of vaccines. Measures such as clarifying vaccine safety and effectiveness, reducing self-funded vaccine prices, offering free vaccination for special groups, strengthening the publicity role of medical staff, and taking advantage of network platforms are essential to reduce vaccine hesitancy among Chinese residents.

Citing Articles

Vaccine Confidence and Coverage among Medical Students at a Federal University in Brazil.

Feijo R, Bertotto J, Pinto A, Leal M, de Souza V, Sakai V Vaccines (Basel). 2024; 12(9).

PMID: 39340025 PMC: 11435744. DOI: 10.3390/vaccines12090993.

The impact of risk perception and institutional trust on COVID-19 vaccine hesitancy in China.

Chen G, Yao Y, Zhang Y, Zhao F Hum Vaccin Immunother. 2024; 20(1):2301793.

PMID: 38282324 PMC: 10826627. DOI: 10.1080/21645515.2024.2301793.

Between now and later: a mixed methods study of HPV vaccination delay among Chinese caregivers in urban Chengdu, China.

Yim V, Wang Q, Li Y, Qin C, Tang W, Tang S BMC Public Health. 2024; 24(1):183.

PMID: 38225563 PMC: 10790461. DOI: 10.1186/s12889-024-17697-6.

The relationship between vaccine acceptance and COVID-19 mortality in Europe: A Cross-Country analysis of public opinion and Epidemiological data.

Brnic S, Buric B, Marcec R, Likic R Vaccine X. 2023; 15:100391.

PMID: 37772201 PMC: 10522863. DOI: 10.1016/j.jvacx.2023.100391.

A qualitative study exploring the social contagion of attitudes and uptake of COVID-19 vaccinations.

Karashiali C, Konstantinou P, Christodoulou A, Kyprianidou M, Nicolaou C, Karekla M Hum Vaccin Immunother. 2023; 19(2):2260038.

PMID: 37758300 PMC: 10538449. DOI: 10.1080/21645515.2023.2260038.

References

Mendonca S, Lorincz R, Boucher P, Curiel D . Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. NPJ Vaccines. 2021; 6(1):97. PMC: 8342436. DOI: 10.1038/s41541-021-00356-x. View

Nguyen K, Srivastav A, Razzaghi H, Williams W, Lindley M, Jorgensen C . COVID-19 Vaccination Intent, Perceptions, and Reasons for Not Vaccinating Among Groups Prioritized for Early Vaccination - United States, September and December 2020. MMWR Morb Mortal Wkly Rep. 2021; 70(6):217-222. PMC: 7877585. DOI: 10.15585/mmwr.mm7006e3. View

Edler C, Klein A, Schroder A, Sperhake J, Ondruschka B . Deaths associated with newly launched SARS-CoV-2 vaccination (Comirnaty®). Leg Med (Tokyo). 2021; 51:101895. PMC: 8052499. DOI: 10.1016/j.legalmed.2021.101895. View

Sallam M, Dababseh D, Eid H, Al-Mahzoum K, Al-Haidar A, Taim D . High Rates of COVID-19 Vaccine Hesitancy and Its Association with Conspiracy Beliefs: A Study in Jordan and Kuwait among Other Arab Countries. Vaccines (Basel). 2021; 9(1). PMC: 7826844. DOI: 10.3390/vaccines9010042. View

Wong L, Wong P, AbuBakar S . Vaccine hesitancy and the resurgence of vaccine preventable diseases: the way forward for Malaysia, a Southeast Asian country. Hum Vaccin Immunother. 2020; 16(7):1511-1520. PMC: 7482793. DOI: 10.1080/21645515.2019.1706935. View

Larson H, de Figueiredo A, Xiahong Z, Schulz W, Verger P, Johnston I . The State of Vaccine Confidence 2016: Global Insights Through a 67-Country Survey. EBioMedicine. 2016; 12:295-301. PMC: 5078590. DOI: 10.1016/j.ebiom.2016.08.042. View

Mallapaty S . WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic. Nature. 2021; 594(7862):161-162. DOI: 10.1038/d41586-021-01497-8. View

Murphy J, Vallieres F, Bentall R, Shevlin M, McBride O, Hartman T . Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom. Nat Commun. 2021; 12(1):29. PMC: 7782692. DOI: 10.1038/s41467-020-20226-9. View

Black C, Yue X, Ball S, Fink R, de Perio M, Laney A . Influenza Vaccination Coverage Among Health Care Personnel - United States, 2017-18 Influenza Season. MMWR Morb Mortal Wkly Rep. 2018; 67(38):1050-1054. PMC: 6188123. DOI: 10.15585/mmwr.mm6738a2. View

10.

Wagner A, Masters N, Domek G, Mathew J, Sun X, Asturias E . Comparisons of Vaccine Hesitancy across Five Low- and Middle-Income Countries. Vaccines (Basel). 2019; 7(4). PMC: 6963484. DOI: 10.3390/vaccines7040155. View

11.

French J, Deshpande S, Evans W, Obregon R . Key Guidelines in Developing a Pre-Emptive COVID-19 Vaccination Uptake Promotion Strategy. Int J Environ Res Public Health. 2020; 17(16). PMC: 7459701. DOI: 10.3390/ijerph17165893. View

12.

Burke P, Masters D, Massey G . Enablers and barriers to COVID-19 vaccine uptake: An international study of perceptions and intentions. Vaccine. 2021; 39(36):5116-5128. PMC: 8299222. DOI: 10.1016/j.vaccine.2021.07.056. View

13.

Lin C, Tu P, Beitsch L . Confidence and Receptivity for COVID-19 Vaccines: A Rapid Systematic Review. Vaccines (Basel). 2021; 9(1). PMC: 7823859. DOI: 10.3390/vaccines9010016. View

14.

Bahri P, Rago L . CIOMS Guide To Vaccine Safety Communication - Executive summary. Vaccine. 2018; 37(3):401-408. DOI: 10.1016/j.vaccine.2018.11.082. View

15.

Rodeghiero F, Balduini C . A new enemy is emerging in the fight against the SARS-CoV-2 pandemic. Haematologica. 2021; 106(8):2040-2041. PMC: 8327714. DOI: 10.3324/haematol.2021.279186. View

16.

Lazarus J, Ratzan S, Palayew A, Gostin L, Larson H, Rabin K . A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2020; 27(2):225-228. PMC: 7573523. DOI: 10.1038/s41591-020-1124-9. View

17.

Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z . Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021; 21(6):803-812. PMC: 7906628. DOI: 10.1016/S1473-3099(20)30987-7. View

18.

Tanriover M, Doganay H, Akova M, Guner H, Azap A, Akhan S . Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021; 398(10296):213-222. PMC: 8266301. DOI: 10.1016/S0140-6736(21)01429-X. View

19.

MacDonald N . Vaccine hesitancy: Definition, scope and determinants. Vaccine. 2015; 33(34):4161-4. DOI: 10.1016/j.vaccine.2015.04.036. View

20.

Zhang M, Zhang T, Shi G, Cheng F, Zheng Y, Tung T . Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China. Expert Rev Vaccines. 2021; 20(7):891-898. PMC: 8127168. DOI: 10.1080/14760584.2021.1925112. View